Speaking of the association with anemia or thrombocytopenia and CD38 expressions, CLL patients with anemia and/or thrombocytopenia had significantly higher plasma levels of CXCL13 and galectin-9 than patients without these complications (p < 0.05, p < 0.0001, and p < 0.0001, respectively). This evidence concerns the gene LGALS9 and anemia (phenotype).